Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) 78.2% HIGHER; is a big winner today after the company said it will continue to develop CPP-109 (version of vigabatrin) for the treatment of cocaine and methamphetamine addiction following a in-depth review of the results from two trials. Click here for the full report.

Radvision (NASDAQ: RVSN) 35.2% LOWER; downgraded at RBC, Cantor Fitzgerald and Morgan Keegan. The downgrades follow news that Cisco will acquire Tandberg, a key competitor of RadVision.

Biofuel Energy (Nasdaq: BIOF) 32.4% HIGHER; today announced that its operating subsidiaries have amended their secured Credit Agreement with